Latent tuberculosis infection in patients with rheumatoid arthritis receiving conventional synthetic disease-modifying antirheumatic drugs: a prospective cross-sectional study from the Himalayas

Rheumatoid arthritis (RA) and its treatments increase the susceptibility to tuberculosis (TB), mainly in TB-endemic settings. Latent TB infection (LTBI) screening is mandatory before biologic disease-modifying antirheumatic drugs. However, data on LTBI among RA patients receiving conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), particularly from north India, are limited. Tuberculin skin testing (TST) may underestimate LTBI in patients with RA because of impaired cell-mediated immunity and reduced delayed-type hypersensitivity responses. In this prospective cross-sectional study, to exclude active TB, 146 consecutive adults with RA (ACR/EULAR 2010 criteria) receiving csDMARDs for ≥3 months underwent Mantoux TST (2 tuberculin units purified protein derivative; reading at 48-72 hours) and chest radiography . Using the conventional cut-off (≥10 mm), LTBI prevalence was 8.2% [12/146; 95% confidence interval (CI) 4.3-13.2%]. Using an immunosuppression-adjusted threshold (≥5 mm), prevalence was 23.3% (34/146; 95% CI 17.8-29.4%). The frequency of 0 mm TST induration was high (76.7%; 112/146). According to univariate analysis, LTBI positivity was linked to higher C-reactive protein (CRP), diabetes, fasting glucose ≥100 mg/dL, current smoking, smoking index >200, and urban residency. In multivariable logistic regression (outcome defined as ≥5 mm), smoking index >200 [adjusted odds ratio (OR) 11.47; 95% CI 1.52-86.6; p=0.018] and higher CRP (adjusted OR 1.036 per mg/L; 95% CI 1.006-1.070; p=0.018) remained independently associated with LTBI. Among RA patients on csDMARDs in a north Indian tertiary center, LTBI prevalence ranged from 8.2% (≥10 mm) to 23.3% (≥5 mm). Application of the ≥5 mm TST threshold substantially increased the estimated LTBI prevalence. The high proportion of participants with 0 mm TST induration suggests reduced TST responsiveness in this population. Further studies incorporating interferon-γ release assays are needed to determine the optimal LTBI screening strategy in patients with rheumatoid arthritis receiving csDMARD therapy.

Authors

Institutions

Publication Details

Journal
Monaldi Archives for Chest Disease
Published
2026-11-16
DOI
https://doi.org/10.4081/monaldi.2026.3953
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Latent tuberculosis infection in patients with rheumatoid arthritis receiving conventional synthetic disease-modifying antirheumatic drugs: a prospective cross-sectional study from the Himalayas

Vikas Sharma, Gautam Prem, Sujata Kaundal Parmar, Ingit Parmar et al.
2 links
Monaldi Archives for Chest Disease
Tuberculosis Research and Epidemiology
article

Latent tuberculosis infection in patients with rheumatoid arthritis receiving conventional synthetic disease-modifying antirheumatic drugs: a prospective cross-sectional study from the Himalayas

Vikas Sharma, Gautam Prem, Sujata Kaundal Parmar, Ingit Parmar, Sunil Sharma
article en

Abstract

Rheumatoid arthritis (RA) and its treatments increase the susceptibility to tuberculosis (TB), mainly in TB-endemic settings. Latent TB infection (LTBI) screening is mandatory before biologic disease-modifying antirheumatic drugs. However, data on LTBI among RA patients receiving conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), particularly from north India, are limited. Tuberculin skin testing (TST) may underestimate LTBI in patients with RA because of impaired cell-mediated immunity and reduced delayed-type hypersensitivity responses. In this prospective cross-sectional study, to exclude active TB, 146 consecutive adults with RA (ACR/EULAR 2010 criteria) receiving csDMARDs for ≥3 months underwent Mantoux TST (2 tuberculin units purified protein derivative; reading at 48-72 hours) and chest radiography . Using the conventional cut-off (≥10 mm), LTBI prevalence was 8.2% [12/146; 95% confidence interval (CI) 4.3-13.2%]. Using an immunosuppression-adjusted threshold (≥5 mm), prevalence was 23.3% (34/146; 95% CI 17.8-29.4%). The frequency of 0 mm TST induration was high (76.7%; 112/146). According to univariate analysis, LTBI positivity was linked to higher C-reactive protein (CRP), diabetes, fasting glucose ≥100 mg/dL, current smoking, smoking index >200, and urban residency. In multivariable logistic regression (outcome defined as ≥5 mm), smoking index >200 [adjusted odds ratio (OR) 11.47; 95% CI 1.52-86.6; p=0.018] and higher CRP (adjusted OR 1.036 per mg/L; 95% CI 1.006-1.070; p=0.018) remained independently associated with LTBI. Among RA patients on csDMARDs in a north Indian tertiary center, LTBI prevalence ranged from 8.2% (≥10 mm) to 23.3% (≥5 mm). Application of the ≥5 mm TST threshold substantially increased the estimated LTBI prevalence. The high proportion of participants with 0 mm TST induration suggests reduced TST responsiveness in this population. Further studies incorporating interferon-γ release assays are needed to determine the optimal LTBI screening strategy in patients with rheumatoid arthritis receiving csDMARD therapy.

Monaldi Archives for Chest Disease
Indira Gandhi Medical College (IN)
Good health and well-being
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon